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Abstract
E7 is one of the best studied proteins of human papillomavirus type 16, largely because of its oncogenic potential linked to
cervical cancer. Yet the sub-cellular location of E7 remains confounding, even though it has been shown to be able to
shuttle between the nucleus and the cytoplasm. Here we show with immunocytochemistry that E7 proteins are located in
the nucleus and cytoplasm in sub-confluent cells, but becomes cytoplasmic in confluent cells. The change in E7’s location is
independent of time in culture, cell division, cell cycle phase or cellular differentiation. Levels of E7 are also increased in
confluent cells as determined by Western blotting. Our investigations have also uncovered how different analytical
techniques influence the observation of where E7 is localised, highlighting the importance of technical choice in such
analysis. Understanding the localisation of E7 will help us to better comprehend the function of E7 on its target proteins.
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Introduction
Human papillomavirus 16 (HPV16) is one of the most prevalent
high-risk HPV types associated with cervical cancer [1,2]. The two
HPV16 oncoproteins E6 and E7 are able to immortalise
keratinocytes [3] and other cell types due to their ability to alter
the levels of various cellular proteins that control cellular
proliferation. The HPV16E6 protein is able to direct p53 protein
for degradation [4,5] and stimulate expression of the catalytic
subunit of telomerase, hTERT [6,7]. The HPV16E7 protein’s
most prominent activity is binding to the tumour suppressor
protein pRb [8]. Hence it is not surprising that the E7 protein of
HPV16 is one of the best studied proteins of the virus. In spite of
this, the location of this protein within the cell is still unclear.
Previous studies investigating the intracellular localisation of
HPV16E7 protein have been equivocal. E7 has been reported by
different groups to be found predominantly in the cytoplasm
[9,10], nucleus [11,12] or both in the nucleus and cytoplasm
[13–15]. A recent study also reported a combination of different
localisation of E7 in the same population of cells [16]. The ability
of E7 to be in the nucleus and/or cytoplasm is by itself not
surprising as it possesses both nuclear import and export signals,
thus allowing it to shuttle between the two compartments [17,18].
However, we are still uninformed in regards to the cellular
circumstances that influence the location of E7 protein in the cell.
To address this question, we used four cell lines, two of which were
derived from naturally occurring cancers that contained integrated
copies of HPV16 DNA (SiHa [19] and CaSki [20]), one derived
from a pre-cancerous lesion containing episomal HPV16 DNA
(W12) [21] and a non-tumorigenic foreskin keratinocyte cell line
NIKS [22], into which episomal HPV16 DNAs were introduced
[23]. Our analyses revealed that the localisation of the E7 protein
is profoundly influenced by cell confluence.
Results
E7 localises into the cytoplasm in confluent cells
We have previously reported the generation of cell lines from
NIKS cells that stably harbour episomal HPV16 DNA [23]. The
viral DNA in these cells is active and they express numerous viral
proteins including the E7 protein. Immunocytochemical staining
of these cells (NIKS+HPV16) revealed that while E7 was present
in the nucleus and the cytoplasm when the cells were sub-
confluent, its location became predominantly cytoplasmic when
the cells were confluent (Figure 1a–b). Confluence was defined by





2. This definition is strictly
adhered to at all times and is implicit in all description in this
report.
To address the possibility that the switch of localisation may be
mediated by interaction between E7 and other proteins that are
expressed from the viral episomes, we generated NIKS cell lines
that only expressed the HPV16E7 protein. We infected NIKS cells
with retroviruses bearing the HPV16E7 gene (LXSN16E7) and
staining of these cells (NIKS+E7) revealed that the E7 protein was
present in the nucleus and cytoplasm when the cells were not
confluent but it became strongly cytoplasmic upon cell confluence,
demonstrating that this phenomenon is independent of other HPV
proteins (Figure 2).
To determine if this phenomenon was specific to NIKS cells,
which were derived from foreskin, we stained for the E7 protein in
W12 cells. W12 cells were originally derived from a low-grade
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21501Figure 1. E7 expressed from episomes localises in the cytoplasm in confluent cells. (a) Immunofluorescence of HPV16E7 protein in sub-
confluent and confluent NIKS+HPV16 cells. NIKS cells (with no HPV16) were analysed in parallel as a negative control. (b) Confocal microscopy of
HPV16E7 protein in sub-confluent and confluent NIKS+HPV16 cells.
doi:10.1371/journal.pone.0021501.g001
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observed the confluence-dependent localisation of E7 proteins
(Figure 3a). This results demonstrate that the switch in E7
localisation is independent of the gender of the cells and the tissue
from which these cells were derived (foreskin and cervix). However,
a common feature between NIKS and W12 cells is that they were
not derived from cancerous tissues. To test if this oncoprotein’s
confluence-dependent relocalisation also occurs in cancer cells,
tumour cell lines CaSki [20] and SiHa [19], which contain
integrated copies of HPV16 DNA, were subjected to similar
(confluent and non-confluent) growth conditions and stained for E7
proteins. We found that the E7 protein in these cells also behaved in
the same way as those in NIKS and W12 cells (Figure 3b–c). These
results confirmed that this phenomenon is neither cell-type nor cell
state (transformed or not) specific. It is interesting to note that E7
levels were heterogeneous between cells in a population. While this
could be due to cells possessing varied copy numbers of episomal
HPV16 DNA (as in the case of W12), it is clear that other unknown
factors must also be involved, as SiHa and CaSki cells (with
integrated HPV16 DNA) also exhibited heterogenous E7 protein
levels between cells of the same population.
The relocation of E7to thecytoplasm was observed irrespective of
whether cell confluence was attained by culturing the cell for several
days longer after non-confluent cells were collected for analyses, or
seeding different amounts of cells inseparate dishes inorder to attain
either non-confluent or confluent (as numerically defined above)
populations the same number of days after seeding. This
demonstrates that the reduction of E7 in the nucleus of confluent
cells is not influenced by trypsinisation, nutrient and growth factor
availability during media changes or by time in culture.
The analyses carried out thus far have been immunocytochem-
ical staining of the E7 protein. While this is undoubtedly the best
way to ascertain the location of proteins in situ, it does not show us
the relative quantities of the E7 proteins in the different populations
of cells. Immunoblotting of whole cell extracts showed levels of E7
increase in confluent NIKS+HPV16 cells (Figure 4a). What is
perplexing however, is that when the cells were fractionated to
nuclear and cytoplasmic lysates, E7 protein appeared predomi-
nantly cytoplasmic in both cell populations (Figure 4b). This was
repeatedly observed using different fractionation protocols. The
balance of relative quantities of cytoplasmic and nuclear E7 did not
reflect the in situ situation that was revealed through immunocyto-
Figure 2. E7 expressed alone localises in the cytoplasm in confluent cells. Immunofluorescence of HPV16E7 protein in sub-confluent and
confluent NIKS+E7 cells (only expressing E7). NIKS cells (vector control) were analysed in parallel as a negative control.
doi:10.1371/journal.pone.0021501.g002
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example Smith-McCune et al. who commented that while Western
blotting-fractionation analyses show E7 to be cytoplasmic, immu-
nocytochemical analyses demonstrated E7 to also be nuclear,
prompting the suggestion that E7 leaks out of the nucleus during
fractionation [24,25]. This suggestion is consistent with our
observations and highlights another confounding factor that
influences the results in this area of research.
Blocking nuclear export inhibits cytoplasmic localisation
of E7 in confluent cells
It has been suggested that the E7 protein forms spherical
oligomers in the cytoplasm [26]. It is possible that in confluent
cells, the E7 proteins are held strongly in the cytoplasm in such
oligomeric structures, which may be static. To determine whether
E7 proteins form a static cytoplasmic presence in confluent cells,
we treated NIKS+HPV16 cells with leptomycin B, which inhibits
Figure 3. E7 in cell lines derived from a pre-cancerous lesion and naturally occurring cancers localises in the cytoplasm in confluent
cells. Immunofluorescene of HPV16E7 protein in sub-confluent and confluent (a) W12, (b) CaSki and (c) SiHa cells.
doi:10.1371/journal.pone.0021501.g003
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effectively prevented cyclin B in these cells from exiting the nucleus
and as a consequence cyclin B, which is normally a cytoplasmic
protein, became almost exclusively nuclear (Figure 5a). Analyses of
the E7 protein in these confluent cells revealed that inhibition of
nuclear export by leptomycin B has also caused the E7 protein to
become predominantly nuclear (Figure 5b); suggesting that the
cytoplasmic presence of E7 is not static, and that an active and
constant export of E7 into the cytoplasm is necessary to keep E7
predominantly cytoplasmic in confluent cells. It is perhaps of
interest to note that while leptomycin B excluded cyclin B from the
cytoplasm almost completely, a certain amount of E7 protein
Figure 4. Levels of E7 increase in confluent cells. Western blotting of HPV16E7 protein in sub-confluent and confluent NIKS and NIKS+HPV16




PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21501Figure 5. Blocking nuclear export inhibits cytoplasmic localisation of E7 in confluent cells. (a) Immunofluorescence of cyclin B1 used as a
positive control for nuclear export inhibition in confluent NIKS+HPV16 cells treated with leptomycin B. (b) Immunofluorescence of HPV16E7 protein in
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but detectable proportion of cytoplasmic E7 protein might actually
be static. This however does not detract from the fact that the vast
majority of E7 proteins in confluent cells require constant nuclear
export to retain them in the cytoplasm.
Cytoplasmic localisation of E7 is not linked to the cell
cycle
As confluence is often associated with cell cycle arrest, we tested
whether the confluence-dependent cytoplasmic localisation of the
E7 protein was coupled to the termination of cell proliferation. To
determine the proliferative state of confluent cultures of
NIKS+HPV16 cells, we labelled sub-confluent and confluent cells
with EdU (alternative to BrdU), which is a nucleotide analogue
and is incorporated into DNA-replicating cells. Even though there
was a reduction in the number of replicating cells in confluent
cultures compared to sub-confluent ones, virtually half (49%) of all
the confluent cells were still proliferating (Figure 6). This figure
contrasts with that of confluent cells that had predominantly
cytoplasmic E7 protein in at least 80% of the cells (Figure 1);
suggesting that the localisation of E7 to the cytoplasm is not
coupled to cessation of cellular proliferation.
Next we investigated if the cytoplasmic localisation of E7 was
associated with a particular phase of the cell cycle. NIKS+HPV16
cells were arrested at G1, S, G2 or mitosis with mimosine,
thymidine, etoposide and nocodazole respectively. The blocked
states of these cells were confirmed by their DNA content through
flow cytometry. Staining for the E7 proteins in these cells shows
that none of the sub-confluent drug-arrested cells at any of the
phases have E7 localised predominantly to the cytoplasm as
observed in confluent cells (Figure 7).
Confluent keratinocytes are known to undergo some form of
early stage differentiation. To test whether early-stage cellular
differentiation was responsible for E7’s confluence-induced
cytoplasmic localisation, we induced differentiation of sub-
confluent NIKS-HPV16 cells with high calcium together with
growth factor withdrawal. While this did indeed stimulate early-
stage differentiation of the sub-confluent cells, as evidenced by
cytokeratin 10 expression, E7 did not re-localise to the cytoplasm
as they do in confluent cells (data not shown).
Collectively, these results show that while the cytoplasmic
localisation of E7 is linked to cell confluence, it is not due to the
cessation of proliferation, the arrest at a particular cell cycle phase
or differentiation of these confluent cells. Instead it appears that a
yet-to-be elucidated mechanism triggered by greater cell-cell
contact between confluent cells underlies the cause for the
cytoplasmic localisation of E7.
Targets of E7 at sub-confluence and confluence
Next, we turned our attention to the effect of this phenomenon
on E7’s activity. We analysed the levels of three binding partners
of E7; pRb [8], SRC-1 [28] and p130 [24,29]. Regardless of E7’s
location, it was able to cause the reduction of these proteins
(Figures 8 and 9). pRb levels were reduced to a similar extent in
both confluent and sub-confluent cells (Figure 8). Interestingly, this
was not the case for SRC-1 and p130 (Figure 9). In spite of the big
increase in the levels of these proteins in confluent cells, E7 protein
was still able to reduce their levels. This may be due to higher E7
levels, but it is also possible that the localisation of E7 to the
cytoplasm is a contributing factor. Whatever the case may be, it is
important to note that cell confluence has a large impact on the
magnitude of reduction of some E7 targets such as SRC-1. SRC-1
was previously reported to be a binding partner of E7 but was not
observed to be reduced by E7. However, when confluent cells
were analysed, the reduction of SRC-1 was much more obvious
and significant. Hence the effect of E7 on the protein level of some
of its binding partners can escape notice in experiments where cells
are not confluent.
Discussion
We have addressed the long-standing confusion regarding the
sub-cellular localisation of the HPV16E7 oncoprotein. By
employing a quantitative definition of confluence (as defined by
number of cells/cm
2), and using several different cell lines that
harbour the viral DNA either as integrated copies in the hosts
genome or as extra-chromosomal self-replicating genomes, we
have demonstrated that the E7 protein’s location within the cells is
profoundly influenced by the confluence of the host cell. In sub-
confluent cells, E7 is present in both the nucleus and cytoplasm,
but in confluent cells the E7 protein becomes predominantly
cytoplasmic with increased protein levels. As such, it is possible
that much of the conflicting reports on E7’s localisation within the
cell were caused by analyses that were carried out on cells of
different confluence. Cell-based experiments are traditionally
carried out at sub-confluence or mid-log phase of growth.
However, in the case of HPV16E7, which is normally expressed
in keratinocytes of the mucosal epithelium where cells are tightly
packed together, assaying cells at confluence is probably a more
informative experimental set-up. Consistent with this view, E7 has
been found to be predominantly cytoplasmic in some patient
biopsies [14,16].
The switch of E7 localisation was very clear when analysed by
immunocytochemistry. However, when sub-cellular fractionation
was used together with Western blotting, E7 was found to be
predominantly in the cytoplasm in both samples, despite using
different protocols for fractionation. This discrepancy of Western
blotting detecting cytoplasmic E7 and immunocytochemistry
detecting both nuclear and cytoplasmic E7 has also been noted
by others. It has been suggested that E7 may leak to the
cytoplasmic fraction during cellular fractionation [24,25]; a
suggestion that we find to be very consistent with our comparative
analyses. Immunocytochemistry samples on the other hand, were
fixed in paraformaldehyde before analysis; preventing any leakage
of E7 and permitting the detection of E7 in situ. As such we were
able to detect E7 both in the nucleus and/or in the cytoplasm,
depending on the confluence of the cells. These observations show
that the profound influence of analytical procedures on the
Figure 6. Localisation of E7 is not linked to cellular prolifer-
ation. Sub-confluent and confluent NIKS and NIKS+HPV16 cells were
treated with EdU (BrdU alternative) to label cells undergoing DNA




PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21501Figure 7. Cytoplasmic localisation of E7 is not linked to the cell cycle. Immunofluorescence of HPV16E7 protein in sub-confluent NIKS+E7
treated with different compounds to arrest the cell cycle at different stages. (a) Confluent control (b) untreated sub-confluent control and sub-
confluent (c) mimosine (G1 block), (d) thymidine (S-phase block), (e) etoposide (G2 block) and (f) nocodazole (mitosis block). Cell cycle blocks were
confirmed in parallel by propidium iodide staining analysed by flow cytometry.
doi:10.1371/journal.pone.0021501.g007
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carefully considered when analysing the E7 protein.
Since a switch in E7 localisation has not been previously
described and characterised, we could not benefit from past
experience to obtain clues as to the possible molecular causes and
mechanisms. Hence we began the characterisation of this switch
by considering the known cellular events that are associated with
cell confluence. These are cessation of proliferation, arrest within a
particular phase of the cell cycle and differentiation; none of which
were found to be associated with the cytoplasmic localisation of E7
in confluent cells. Interestingly, Dreier et al. [16] reported that they
observed the E7 proteins to be present predominantly in large
structures encompassing the chromosomes in metaphase and
telophase cells. We, on the other hand, did not observe this in cells
arrested in mitosis. As can be seen in Figure 7f, nocodazole, which
was used to arrest cells in mitosis, did not cause nuclear membrane
dissolution or chromosome condensation, which are features of
late metaphase and telophase cells. Together these observations
suggest that while E7 location within the cell is not altered
throughout interphase, it becomes clustered around condensed
DNA in the absence of a nuclear membrane. However, as this only
occurs when the nuclear membrane is no longer present, it would
not be appropriate to conclude that the location of the E7 protein,
in respect to the nucleus and cytoplasm, changes as a function of
the cell cycle.
Although the general observation of Dreier et al. regarding E7
localisation in both the cytoplasm and nuclei of interphase cells is
similar to that of ours, the detailed pattern of E7 protein staining
between the two studies are somewhat different. Dreier et al.
observed that cells in interphase had a predominantly diffuse
cytoplasmic E7 with a ring structure surrounding the nucleus and
faint nuclear E7 microstructures. This difference is most likely
brought about by the different antibodies used. While we
employed a cocktail of commercially-available E7 antibodies,
Dreier et al. generated their own rabbit monoclonal antibody
against the HPV16E7 protein. With these new reagents, it would
be possible in the near future to see the E7 micro-structures in
confluent and non-confluent cells expressing E7, which might be
more informative. At the moment, we have to conclude that a yet-
to-be elucidated mechanism triggered by greater cell-cell contact
underlies the shift of E7 from being cytoplasmic and nuclear to
almost purely cytoplasmic.
It has been reported that E7 exists as dimers in the nucleus and
as spherical oligomers in the cytosol [26]. Hence, it would mean
that confluence could favour the formation of E7 oligomers. It
would be interesting to study how this is brought about and our
observation that confluence can cause E7 to alternate between the
two forms could help to delineate the dynamics of the E7 form in
the living cell. The fact that E7 exist as dimers in the nucleus may
also explain the ease by which it escapes into the cytoplasmic
fraction during cellular fractionation. Another interesting obser-
vation is that even when E7 is cytoplasmic, it can still be rendered
predominantly nuclear by leptomycin B, suggesting that E7 still
shuttles between the nucleus and cytoplasm. This is consistent with
the ability of E7 to act on its target proteins regardless of its
predominant location. On this point, our experiments with SRC-1
also demonstrates that consideration of cellular confluence when
experimenting with E7 is pivotal, as failure to do so may allow E7’s
activity on some cellular proteins to pass un-noticed due to the
small magnitude of change observed in sub-confluent cells. A hint
of how E7’s localisation is connected to its activity can be seen in
regards to p130 protein degradation. We observed that the level of
this protein rose drastically in confluent NIKS cells, yet in
confluent NIKS+HPV16 cells the p130 protein level was very
efficiently reduced by E7; which is present almost exclusively in the
cytoplasm of these confluent cells. This could indicate that the
degradation of p130 is carried out predominantly in the
cytoplasm. As it happens, this is indeed the case, as reported
Barrow-Laing et al. who demonstrated that while p130 can be
degraded by HPV16E7 in the nucleus, the bulk activity of p130
degradation by HPV16E7 occurs in the cytoplasm [29].
Interestingly, the low-risk HPV6E7 protein appears to operate
differently, whereby it is equally able to degrade p130 in the
nucleus as well as in the cytoplasm. When suitable antibodies to
HPV6E7 become available, it would be very interesting to analyse
the sub-cellular localisation of the HPV6E7 in relation to cell
confluence and ascertain if this could be the link to the difference
Figure 8. Effect of E7 on pRb at sub-confluence and confluence.
Western blot analysis of pRb in sub-confluent and confluent NIKS and
NIKS+E7 cells. HSP70 is shown as a loading control. Graphs show
integrated density measured by ImageJ and normalised to HSP70 for
the blots shown. Two replicates were analysed for the reduction of pRb
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important to investigate how other activities of E7 are related to its
concentration and location within the cell. Apart from resolving
the puzzling question of E7 location in the cell, this work has also
raised two interesting questions; the exact pathway that promotes
increased levels of E7 and cytoplasmic localisation in confluent
cells and the effect of this on other reported E7 activities. The
elucidation of these, will undoubtedly teach us more about the
activities of this very interesting oncoprotein.
Materials and Methods
Cell culture
NIKS provided by Dr Paul Lambert and W12 provided by Dr
Margaret Stanley were cultured in F-medium (three parts F-12
Ham:1 part Dulbecco’s modified Eagle’s medium, 5% fetal calf
serum, 24 mg/ml adenine, 8.4 ng/ml cholera toxin, 5 mg/ml
insulin, 0.4 mg/ml hydrocortisone and 10 ng/ml epidermal
growth factor) with lethally irradiated J2-3T3 [30] feeder cells.
J2-3T3 and SiHa were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum. CaSki were
cultured in RPMI-1640 medium supplemented with 10% fetal calf
serum.
Recircularisation of HPV16 DNA and NIKS+HPV16
Recircularised HPV16 DNA was generated from the pSPW12
plasmid, provided by Dr Margaret Stanley. Five micrograms of
pSPW12 was digested with BamHI to release the full-length
HPV16 DNA, followed by a ligation reaction with 2000 U of New
England Biolab’s T4DNA ligase in a volume of 2 ml at 16uC
Figure 9. Effects of E7 on SRC-1 and p130 at sub-confluence and confluence. Western blot analysis of (a) SRC-1 and (b) p130 in sub-
confluent and confluent NIKS and NIKS+HPV16 cells. HSP70 is shown as a loading control. Graphs show integrated density measured by ImageJ and
normalised to HSP70 for the blots shown. Three replicates were analysed for the reduction of SRC-1 and p130 and the error bars show standard
deviation. On average the drop in levels of SRC-1 was 4.37 fold more and p130 was 7.40 fold more in confluent cells compared to sub-confluent cells.
doi:10.1371/journal.pone.0021501.g009
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was purified and concentrated using the Qiagen miniprep kit
according to the protocol provided. To generate NIKS harbouring
episomal HPV16 DNA (NIKS+HPV16) 0.5 million NIKS were
transfected with 0.8 mg of recircularised HPV16 DNA and 0.2 mg
of pCDNA6A (Invitrogen, Carlsbad, CA) with Effectene transfec-
tion reagent (Qiagen). The cells were selected with 8 mg/ml of
blasticidin until all untransfected control cells were dead.
Retrovirus production and NIKS+E7
Retroviral vectors LXSN empty vector control and LXSN16E7,
were kindly provided by Dr Denise Galloway. The vectors were
transfected into Phoenix A cells (kindly provided by Dr Nolan),
and the medium of the cells harvested 48 h later and filtered
through a 0.2 mm filter. To generate NIKS expressing E7 alone
(NIKS+E7), cells were infected with the retroviruses mixed with
polybrene at a concentration of 10 mg/ml and layered onto NIKS.
Neomycin was used at 500 mg/ml concentration for selection.
E7 immunofluorescence microscopy
Coverslips from cell culture were washed in PBS, fixed in 4%
paraformaldehyde in PBS for 10 min and washed three times in
PBS. The coverslips were then permeabilised for 10 min with
0.1% Triton X-100 (Sigma-Aldrich) in PBS, rinsed once with PBS
and blocked in 0.1% BSA (Sigma-Aldrich) in PBST (PBS with
0.1% Tween 20 [Sigma-Aldrich]) for 30 min. The samples were
incubated with the E7 primary antibodies (Zymed clone 8C9 and
Santa Cruz clone ED17) at 1:500 in the blocking solution for 4 h,
washed 4 times with PBST and incubated for 1.5 h with secondary
antibody AlexaFluor488 (A11029, Molecular Probes) at 1:400 in
the blocking solution. The coverslips were washed 4 times with
PBST and nuclei were stained with DAPI (Invitrogen) for 20 min.
Fixing, permeabilisation, blocking and staining were all at room
temperature. Images were captured using a Leica DMI4000 or a
Leica SP2 confocal microscope.
Western blotting
NIKS cells were harvested after the removal of the J2-3T3
feeder layer and lysed with RIPA (150 mM NaCl, 1% TritonX,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris [pH 8.0],
0.005 mM EDTA [pH 8.0]), TEN buffer (50 mM Tris [pH 7.4],
150 Mm NaCl, 1 mM EDTA, 1% NP-40) or for cytoplamic and
nuclear fractionation NE-PER nuclear and cytoplasmic extraction
reagent kit (ThermoScientific). All buffers were supplemented with
a protease inhibitor cocktail (Bio-Rad, Hercules, CA). The protein
lysates were quantified by the Bradford method and stored at
270uC. Proteins were separated on 8, 10 or 15% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, transferred onto poly-
vinylidene difluoride membrane, blocked in 5% milk in PBS–0.5%
Tween20 and probed with E7 (Zymed clone 8C9, Santa Cruz
clone ED17, 716-325 and NM2), pRb (BD Pharmingen clone G3-
245), p130 (Santa Cruz clone C-20) or SRC-1 (Upstate clone
1135) followed by appropriate HRP-linked secondary antibodies.
Blocking nuclear export with Leptomycin B
Leptomycin B (L2913 Sigma) was added to the culture medium
for 3 h at 20 ng/ml. The coverslips were harvested as described
and stained for E7. Cells from the same cultures were stained for
CyclinB1 (BD Pharmingen clone GNS11) to control for inhibition
of nuclear export.
EdU staining
Cells were treated with EdU (Click-iT EdU kit C10085,
Invitrogen) for 25 h to label cells undergoing DNA synthesis. The
cells were stained for EdU according to the manufacturer’s
instructions and the percentage of labelled cells was calculated
(.100 cells counted/sample).
Cell cycle block
Sub-confluent cells were treated with different compounds to
arrest the cell cycle at different stages. Mimosine (SigmaAldrich) at
400 uM for 16 h for a G1 block, Thymidine (SigmaAldrich) at
2 mM for 16 h for a S-phase block, Etoposide (SigmaAldrich) at
1 uM for 24 h for a G2 block and Nocodazole (SigmaAldrich) at
40 ng/ml for 24 h for a mitosis block. An untreated sub-confluent
and confluent control were also included. Cell cycle blocks were
confirmed in parallel by propidium iodide staining analysed by flow
cytometry. For propidium iodide staining the cells were trypsinised
and fixed in ice-cold 70% ethanol, treated with 0.2 mg/ml of
RNAseA (SigmaAldrich) for 15 minutes at 37uC and stained with
40 mg/ml propidium iodide (SigmaAldrich) for 15 minutes.
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